Maravai LifeSciences (NASDAQ: MRVI) insider transactions
In the twelve months to 10 November 2026, executives and directors of Maravai LifeSciences reported 2 open-market sales of 50,000 shares ($254,000) and 5 open-market purchases of 566,771 shares ($1.9m), by 3 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 30 October 2026 | Asarpota Rajesh | Chief Financial Officer | Shares withheld for tax | −5,466 | $8.46 | 286,203 | Form 4 |
| 8 October 2026 | Brust Bernd | Chief Executive Officer | Shares withheld for tax | −29,250 | $7.43 | 1,531,999 | Form 4 |
| 30 September 2026 | Asarpota Rajesh | Chief Financial Officer | Shares withheld for tax | −5,465 | $7.65 | 418,021 | Form 4 |
| 8 September 2026 | Brust Bernd | Chief Executive Officer | Shares withheld for tax | −29,250 | $7.32 | 1,561,249 | Form 4 |
| 31 August 2026 | Asarpota Rajesh | Chief Financial Officer | Shares withheld for tax | −5,465 | $7.68 | 423,486 | Form 4 |
| 10 August 2026 | Brust Bernd | Chief Executive Officer | Shares withheld for tax | −29,250 | $6.23 | 1,590,499 | Form 4 |
| 30 July 2026 | Asarpota Rajesh | Chief Financial Officer | Shares withheld for tax | −5,465 | $6.59 | 428,951 | Form 4 |
| 8 July 2026 | Brust Bernd | Chief Executive Officer | Shares withheld for tax | −29,250 | $5.92 | 1,619,749 | Form 4 |
| 30 June 2026 | Asarpota Rajesh | Chief Financial Officer | Shares withheld for tax | −65,584 | $6.39 | 434,416 | Form 4 |
| 10 June 2026 | Oreshack Kurt | General Counsel | Open-market sale, 10b5-1 plan | −25,000 | $5.10 | 335,767 | Form 4 |
| 9 June 2026 | Lucier Gregory T | Director | Gift | −46,293 | — | 155,123 | Form 4 |
| 9 June 2026 | Lucier Gregory T | Director | Gift | +46,293 | — | 156,077 | Form 4 |
| 9 June 2026 | Oreshack Kurt | General Counsel | Open-market sale, 10b5-1 plan | −25,000 | $5.06 | 360,767 | Form 4 |
| 8 June 2026 | Brust Bernd | Chief Executive Officer | Shares withheld for tax | −351,001 | $5.02 | 1,648,999 | Form 4 |
| 26 May 2026 | Eckert R Andrew | Director | Grant or award | +46,293 | — | 412,183 | Form 4 |
| 26 May 2026 | Lucier Gregory T | Director | Grant or award | +46,293 | $4.38 | 201,416 | Form 4 |
| 26 May 2026 | Mihas Constantine S | Director | Grant or award | +46,293 | — | 184,348 | Form 4 |
| 26 May 2026 | DeFord John A | Director | Grant or award | +46,293 | — | 205,478 | Form 4 |
| 26 May 2026 | Cunningham Sean Laurence | Director | Grant or award | +46,293 | — | 184,348 | Form 4 |
| 26 May 2026 | Marker Luke Joseph | Director | Grant or award | +46,293 | — | 184,348 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Maravai LifeSciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.